Physician profile
Stephen E Metzinger
NPI 1477502474
$5,894.31
in general payments reported to CMS, 2019-2025
17 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,283 · 2020: $1,708 · 2021: $348 · 2022: $37.32 · 2023: $224 · 2024: $64.05 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes Gmbh | $4,499.30 | 2019-2020 | |
| Abbvie INC. | $232.89 | 2023-2025 | |
| Allergan, INC. | $162.40 | 2019-2022 | |
| Integra Lifesciences Corporation | $158.83 | 2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Medtronic, INC. | $150.00 | 2021 | |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Merz North America, INC. | $123.30 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $123.12 | 2019 | |
| Mentor Worldwide LLC | $58.55 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $42.47 | 2025 | Nuzyra |
| Baxter Healthcare | $36.66 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $36.61 | 2019-2021 | |
| Tela Bio, INC. | $31.48 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Galderma Laboratories, L.P. | $30.60 | 2019-2023 | Dysport |
| Heron Therapeutics, INC. | $22.95 | 2023 | Zynrelef |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $21.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.48 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Metzinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.